Opioid Therapy for Osteoarthritis and Chronic Low Back Pain

被引:16
作者
Altman, Roy D. [1 ]
Smith, Howard S. [2 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Rheumatol & Immunol, Los Angeles, CA 90024 USA
[2] Albany Med Coll, Dept Anesthesiol, Albany, NY 12208 USA
关键词
chronic low back pain; osteoarthritis; opioids; OXYMORPHONE EXTENDED-RELEASE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; LIDOCAINE PATCH 5-PERCENT; CHRONIC NONCANCER PAIN; DICLOFENAC SODIUM GEL; INDUCED RESPIRATORY DEPRESSION; OBESE OLDER-ADULTS; KNEE OSTEOARTHRITIS; DOUBLE-BLIND; CYCLO-OXYGENASE-2; INHIBITORS;
D O I
10.3810/pgm.2010.11.2226
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Background: Chronic low back pain (CLBP) and osteoarthritis (OA) of any joint are highly prevalent, occurring in > 50% of US adults aged >= 60 years. Opioids are prescribed more frequently for CLBP and OA than for any other noncancer pain, and the judicious use of opioids is recommended by treatment guidelines for the management of CLBP and OA pain. Objective: To review the appropriate role of opioid analgesics in the treatment of patients with moderate-to-severe pain due to CLBP or OA and provide recommendations for best practices when prescribing opioids. Methods: Articles were identified through a search of PubMed. Additional references were identified for inclusion from the reference lists of articles identified via the literature search, treatment guidelines, and Cochrane Reviews. Results: The available data suggest that opioid therapy represents a valuable treatment option in patients who do not respond to other analgesics and in whom the potential benefits of treatment outweigh the potential risks. Prescribing physicians need to perform vigilant patient screening and monitoring for signs of abuse, intervene promptly to manage or prevent adverse events and drug interactions, tailor opioid therapy to individual patients' comorbidities, and know how to switch or rotate opioids to find the best treatment option. Conclusions: Prescribers need to understand the place of opioid therapy in a multimodal treatment program that includes patient rehabilitation to reduce pain and improve function. The analgesic benefits of opioids must be balanced against concerns about addiction and abuse, adverse events, and their potential impact on other aspects of treatment.
引用
收藏
页码:87 / 97
页数:11
相关论文
共 134 条
[1]
Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways [J].
Adams, M ;
Pieniaszek, HJ ;
Gammaitoni, AR ;
Ahdieh, H .
JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (03) :337-345
[2]
Chapter 4 - European guidelines for the management of chronic nonspecific low back pain [J].
Airaksinen, O. ;
Brox, J. I. ;
Cedraschi, C. ;
Hildebrandt, J. ;
Klaber-Moffett, J. ;
Kovacs, F. ;
Mannion, A. F. ;
Reis, S. ;
Staal, J. B. ;
Ursin, H. ;
Zanoli, G. .
EUROPEAN SPINE JOURNAL, 2006, 15 (Suppl 2) :S192-S300
[3]
Transdermal fentanyl versus sustained release oral morphine in strong-opioid naive patients with chronic low back pain [J].
Allan, L ;
Richarz, U ;
Simpson, K ;
Slappendel, R .
SPINE, 2005, 30 (22) :2484-2490
[4]
Pharmacological Therapies for Osteoarthritis of the Hand A Review of the Evidence [J].
Altman, Roy D. .
DRUGS & AGING, 2010, 27 (09) :729-745
[5]
Diclofenac Sodium Gel in Patients with Primary Hand Osteoarthritis: A Randomized, Double-blind, Placebo-controlled Trial [J].
Altman, Roy D. ;
Dreiser, Renee-Liliane ;
Fisher, Chester L. ;
Chase, Walter F. ;
Dreher, Donatus S. ;
Zacher, Josef .
JOURNAL OF RHEUMATOLOGY, 2009, 36 (09) :1991-1999
[6]
Altman RD, 2010, AM J MANAG CARE, V16, pS41
[7]
[Anonymous], 2007, ULTR ER TRAM HYDR PA
[8]
[Anonymous], OST CAR MAN OST AD
[9]
[Anonymous], GUID IND ASS AB POT
[10]
[Anonymous], 2010, LID PATCH 5 PACK INS